Oligonucleotide Therapeutics Society

Recent Articles

Recent Articles2026-08-24T06:57:48+00:00
13May, 2025

OTS Member Highlight – Holly Kordasiewicz, PhD

Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed neurodegenerative diseases gradually and relentlessly ...

25February, 2025

2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases

In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in 30 years — include an oligonucleotide therapy for blood cancer, an antisense oligonucleotide shown to significantly drop triglyceride levels, and ...

12February, 2025

Transporting Therapeutics: A Novel Approach to Deliver ASOs to the Brain

Antisense oligonucleotide (ASO) therapies, which bind to RNA and modify protein expression, are promising drugs for treating neurological conditions. However, their inability to cross the blood-brain barrier (BBB) sometimes makes injection directly into the cerebral spinal fluid (via intrathecal injection) necessary, which is not without its risks or drawbacks ...

5February, 2025

Oligonucleotide Treatment Advances Offer Relief for Patients with Familial Chylomicronemia Syndrome

At just three weeks old, Darlene was sent to the emergency room after her mom had brought her to a pediatrician. The baby wouldn't stop crying and wasn't eating. Concerningly, her triglyceride levels were in the 20,000's, far over the normal 150 level. Darlene was referred to a lipid ...

9January, 2025

The Man Behind the Molecules: John Maraganore’s RNAi Legacy

The 2024 OTS lifetime achievement winner, John Maraganore, is best known for his pioneering role in making RNA interference (RNAi) a successful therapeutic modality while CEO at Alnylam Pharmaceuticals. However, before joining and after leaving Alnylam, he was and continues to be influential in the biotechnology sphere, with his ...

3December, 2024

Bridge Editing: A Novel Technique for Large-Scale DNA Modifications

Link Source: Hiraizumi, M., Perry, N.T., Durrant, M.G. et al. Structural mechanism of bridge RNA-guided recombination. Nature 630, 994–1002 (2024). Gene editing has swiftly advanced since CRISPR was discovered, with CRISPR being developed not only to provide therapeutic gene editing treatments for humans but also for uses such as basic research, as ...

19November, 2024

Personalized ASO Provides Improvements for a Girl with KAND, an Ultra-rare Disease

Within the world of rare diseases exist conditions so sparse and infrequent they’re called nano-rare — or N of 1  — diseases and typically affect only one to thirty people worldwide (1). While less than 10% of rare diseases have approved treatments, nano-rare or ultra-rare diseases are often entirely ...

Get the latest news!

  • Category

Go to Top